期刊文献+

完善改进绿色通道对急性缺血性卒中患者溶栓率影响的研究 被引量:14

Study on the significance of establishment of green pathway for raising the rate of intravenous thrombolysis in patients with acute ischemic stroke
下载PDF
导出
摘要 目的观察完善院内绿色通道对缩短急性缺血性卒中(AIS)患者从入院到溶栓治疗的时间(DNT)及溶栓率的影响。方法统计2013年1月以来于该院就诊的AIS患者,对总体溶栓率,时间窗内患者溶栓率及DNT进行分析,比较绿色通道完善前后溶栓率及DNT变化情况。结果绿色通道完善改进后,于该院就诊的AIS患者的溶栓率(7.56%)较绿色通道完善改进前(0.62%)明显增加,DNT持续缩短(108 min vs.53 min)。结论通过整改绿色通道流程,可使溶栓率显著提高。证明在院前延误严重,溶栓率较低的地区,完善院内绿色通道,是提高AIS患者溶栓率的重要措施。 Objective To observe the establishment of green pathway in shortening the duration from admission to intravenous thrombolysis and the influence on intravenous thrombolytic rate of patients with acute ischemic stroke( AIS) in this hospital. Methods Patients with AIS in this hospital since January 2013 were screened for the rate of intravenous thrombolysis in patients within the time window and the time for intravenous thrombolysis. The outcome had been compared before and after the establishment of green pathway. Results After establishment of green pathway,the rate of intravenous thrombolysis had been significantly raised from 0. 62% to 7. 56% and the duration from admission to intravenous thrombolysis was significantly shortened from 108 minutes to 53 minutes. Conclusion The improvement in establishing green pathway,can significantly raise the thrombolytic rate in patients with acute ischemic stroke in this hospital. Hence it is important to complete the green pathway in the hospital,and it is an important measure for raising the rate of thrombolysis in patients with acute ischemic stroke( AIS).
出处 《临床和实验医学杂志》 2016年第2期188-190,共3页 Journal of Clinical and Experimental Medicine
基金 邯郸市科学技术研究与发展计划项目(项目编号:1423108063-9)
关键词 急性缺血性卒中 静脉溶栓 绿色通道 Acute ischemic stroke Intravenous thrombolysis Green pathway
  • 相关文献

参考文献9

  • 1Davis SM, Donnan GA, Parsons MW, et al. Effects of aheplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) : a placebo- controlled randomised trial[ J ]. Lancet Neu- tol,2008,7 (4) :299 - 309.
  • 2Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt- PA stroke trials[ J]. Lancet,2004,363(9411 ) :768 -774.
  • 3Lees KR, Bluhmki E, van Kummer R, et al. Time to treatment with in- travenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[ J]. Lancet, 2010, 375(9727) :1695 - 1703.
  • 4各类脑血管疾病诊断要点(1995)[J].临床和实验医学杂志,2013,12(7):559-559. 被引量:479
  • 5无,徐安定,王拥军.重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中中国专家共识(2012版)[J].中华内科杂志,2012,51(12):1006-1010. 被引量:185
  • 6王伊龙,吴敌,周永,赵性泉,王春雪,王拥军.中国七城市卒中患者急诊溶栓情况分析[J].中国卒中杂志,2009,4(1):23-28. 被引量:72
  • 7Meretoja A, Strbian D, Mustanoja S, et al. Reducing inhospital delay to 20 minutes in stroke thrombolysis [ J ]. Neurology,2012,79 ( 4 ) :306 - 313.
  • 8Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke throm- bolysis delays to25 minutes in Melbourne in only4 months[J]. Neurol- ogy,2013,81 (12) :1071 - 1076.
  • 9Jin H, Zhu S, Wei JW, et al. Factors associated with prehospital delays in the presentation of acute stroke in urban China[ J]. Stroke,2012,43 (2) :362 -370.

二级参考文献13

  • 1丁宏岩,董强.基底动脉梗死的治疗:动脉和静脉溶栓效果比较的系统分析[J].中国卒中杂志,2006,1(6):414-416. 被引量:126
  • 2王伊龙.临床应用重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中专家共识[J].中华内科杂志,2006,45(7):613-614. 被引量:52
  • 3J. Schenkel,C. Weimar,T. Knoll,R. L. Haberl,O. Busse,G. F. Hamann,H.-C. Koennecke,H.-C. Diener.R1 – Systemic thrombolysis in German stroke units[J].Journal of Neurology.2003(3)
  • 4Kapral MK.Registry of the canadian strok network progress report2001-2005[RCSN]. http://www.rcsn.org/pdf/RCSN-Techni calReport-final.pdf . 2007
  • 5Schenkel J,Weimar C,Knoll T,et al.R1-systemic thrombolysis in German stroke units--the experience from the German Stroke data bank[].Journal of Neurology.2003
  • 6Tissue plasminogen activator for acute ischemic stroke.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group[].The New England Journal of Medicine.1995
  • 7Hacke W,Kaste M,Fieschi C,et al.Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)[].The Journal of The American Medical Association.1995
  • 8Hacke W,Kaste M,Fieschi C,et al.Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)[].The Lancet.1998
  • 9Clark WM,Wissman S,Albers GW,et al.Recombinant tissue-type plasminogen activator(Alteplase)for ischemic stroke3to5hours after symptom onset.The ATLANTIS Study:a randomized con-trolled trial.Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke[].The Journal of The American Medical Association.1999
  • 10Clark WM,Albers GW,Madden KP,et al.The rtPA(alteplase)0-to6-hour acute stroke trial,part A(A0276g):results of a double-blind,placebo-controlled,multicenter study.Thromblytic therapy in acute ischemic stroke study investigators[].Stroke.2000

共引文献728

同被引文献99

引证文献14

二级引证文献119

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部